Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk.
Insider & Institutional Ownership
83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 7.0% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility and Risk
Regeneron Pharmaceuticals has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.
Profitability
This table compares Regeneron Pharmaceuticals and Mirum Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Regeneron Pharmaceuticals | 27.86% | 13.47% | 10.34% |
| Mirum Pharmaceuticals | -139.18% | -36.28% | -8.54% |
Analyst Recommendations
This is a summary of current ratings for Regeneron Pharmaceuticals and Mirum Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Regeneron Pharmaceuticals | 0 | 8 | 22 | 1 | 2.77 |
| Mirum Pharmaceuticals | 1 | 0 | 13 | 1 | 2.93 |
Regeneron Pharmaceuticals currently has a consensus target price of $846.28, indicating a potential upside of 4.91%. Mirum Pharmaceuticals has a consensus target price of $148.19, indicating a potential upside of 83.57%. Given Mirum Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Mirum Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.
Valuation & Earnings
This table compares Regeneron Pharmaceuticals and Mirum Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Regeneron Pharmaceuticals | $14.34 billion | 5.79 | $4.50 billion | $40.46 | 19.94 |
| Mirum Pharmaceuticals | $521.31 million | 10.05 | -$23.36 million | ($14.55) | -5.55 |
Regeneron Pharmaceuticals has higher revenue and earnings than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Regeneron Pharmaceuticals beats Mirum Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
